Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,099.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price boosted by UBS Group from $1,090.00 to $1,099.00 in a report issued on Wednesday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently commented on the company. StockNews.com upgraded Regeneron Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday, April 12th. Royal Bank of Canada restated an outperform rating and set a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a research note on Wednesday, March 13th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a research note on Monday, February 5th. Finally, Cantor Fitzgerald restated a neutral rating and set a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, April 15th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus target price of $976.41.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $896.82 on Wednesday. The stock has a market cap of $98.43 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 2.60 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock has a 50 day moving average of $953.01 and a 200-day moving average of $891.10. Regeneron Pharmaceuticals has a 52 week low of $684.80 and a 52 week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The business’s revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted $10.96 EPS. On average, analysts expect that Regeneron Pharmaceuticals will post 38.59 EPS for the current fiscal year.

Insider Activity

In other news, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction on Tuesday, January 23rd. The stock was sold at an average price of $950.00, for a total transaction of $2,571,650.00. Following the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at $6,062,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Joseph L. Goldstein sold 2,707 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the transaction, the director now directly owns 6,382 shares of the company’s stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,729 shares of company stock valued at $13,124,641. Company insiders own 8.83% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REGN. Sunbelt Securities Inc. bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $25,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $26,000. West Paces Advisors Inc. boosted its stake in Regeneron Pharmaceuticals by 575.0% during the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. O Dell Group LLC bought a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $27,000. Finally, Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.